MENET | 868686-01-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: MENET
• 英文别名: (2S,3S)-2-[α-(2-methylphenoxy)phenylmethyl]morpholine；(S)-2-((S)-Phenyl-o-tolyloxy-methyl)-morpholine；4T66VH9Cfl；(2S)-2-[(S)-(2-methylphenoxy)-phenylmethyl]morpholine
• CAS: 868686-01-5
• 化学式: C₁₈H₂₁NO₂
• 分子量: 283.37
• InChiKey: BTDIKAPSRZPGSC-ROUUACIJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  30.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  (2S,3S)-N-tert-butoxycarbonyl-2-[α-(2-methylphenoxy)phenylmethyl]morpholine 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 以79%的产率得到MENET
  参考文献：
  名称：

  Synthesis, Radiosynthesis, and Biological Evaluation of Carbon-11 and Fluorine-18 Labeled Reboxetine Analogues: Potential Positron Emission Tomography Radioligands for in Vivo Imaging of the Norepinephrine Transporter

  摘要：

  Reboxetine analogues with methyl and fluoroalkyl substituents at position 2 of the phenoxy ring 1-4 were synthesized. In vitro competition binding with [H-3]nisoxetine demonstrated that 1-4 have a high affinity for the norepinephrine transporter (NET) with K-i's = 1.02, 3.14, 3.68, and 0.30 nM, respectively. MicroPET imaging in rhesus monkeys showed that the relative regional distribution of [C-11]1 and [C-11]4 is consistent with distribution of the NET in the brain, while [F-18]2 and [F-18]3 showed only slight regional differentiation in brain uptake. Especially, the highest ratios of uptake of [C-11]1in NET-rich regions to that in caudate were obtained at 1.30-1.45 at 45 min and remained relatively constant over 85 min. Pretreatment of the monkey with the selective NET inhibitor, desipramine, decreased the specific binding for both ["C]l and [C-11]4. PET imaging in awake monkeys suggested that anesthesia influenced the binding potential of [C-11]1 and [C-11]4 at the NET.

  DOI：

  10.1021/jm800817h

文献信息

• Substituted morpholine compounds for the treatment of central nervous system disorders
  申请人：Barta S. Nancy

  公开号：US20050245519A1

  公开（公告）日：2005-11-03

  This invention relates to compounds of the formulae I wherein R 1 -R 8 , A, X, and Z are defined as in the specification, pharmaceutical compositions containing them and their use in the treatment of central nervous system disorders.

  这项发明涉及到公式I中的化合物，其中R1-R8，A，X和Z的定义如规范中所述，包含它们的药物组合物以及它们在治疗中枢神经系统疾病中的用途。
• SUBSTITUTED MORPHOLINE COMPOUNDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS
  申请人：Warner-Lambert Company LLC

  公开号：EP1745029A1

  公开（公告）日：2007-01-24
• US7659394B2
  申请人：——

  公开号：US7659394B2

  公开（公告）日：2010-02-09
• [EN] SUBSTITUTED MORPHOLINE COMPOUNDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS<br/>[FR] COMPOSES DE MORPHOLINE SUBSTITUES PERMETTANT DE TRAITER DES TROUBLES DU SYSTEME NERVEUX CENTRAL
  申请人：WARNER LAMBERT CO

  公开号：WO2005105763A1

  公开（公告）日：2005-11-10

  This invention relates to compounds of the formulae (I), (II), (III), wherein R'- Re, A, X, and Z are defined as in the specification, pharmaceutical compositions containing them and their use in the treatment of central nervous system disorders.
• [EN] PREPARATION OF FLUORINE-LABELLED COMPOUNDS<br/>[FR] PRÉPARATION DE COMPOSÉS MARQUÉS PAR DU FLUOR
  申请人：ISIS INNOVATION

  公开号：WO2010007363A2

  公开（公告）日：2010-01-21

  The invention relates to a process for producing a fluorine-labelled compound, the process comprising: (a) treating a compound of formula (I) wherein R1, R2 and the C(H) group to which R1 and R2 are bonded together form a moiety to be labelled with fluorine; and the fluorous tag is a group of formula (II) wherein Rf is a straight-chained or branched C4-I2 perfluoroalkyl group; and L is a single bond, -alk-, -arylene-, -alk-arylene-, alk-X-, -arylene-X-, -alk-arylene-X, -alk- X-arylene-, -alk-X-arylene-X-, -arylene-alk-, -arylene-X-alk-, -arylene-alk-X- or - arylene-X-alk-X-, wherein X is N(R"), O, S, C(O) or C(O)N(R") and wherein alk is unsubstituted or substituted C1-10 alkylene which is optionally interrupted by N(R"), O, S, C(O), C(O)N(R") or arylene, wherein R" is C1-6 alkyl or aryl; with [nF], wherein nF is 18F or 19F, thereby fluorinating and detagging the compound of formula (I) to produce a fluorine-labelled compound of formula (III) The invention further relates to compounds of formula (I), a process for producing such compounds, and a combination product which comprises the two reactants used in that process.